コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 echnical challenges to developing successful cell therapy.
2 eta, suggesting a novel approach to adoptive cell therapy.
3 rucial role of cell dose in the responses to cell therapy.
4 ies such as checkpoint blockade and adoptive cell therapy.
5 peutic benefits associated with CD34(+) stem cell therapy.
6 of cardiac functions similar to cardiac stem cell therapy.
7 orably condition CD8(+) T cells for adoptive cell therapy.
8 eceived chimeric antigen receptor-modified T cell therapy.
9 urs in many autoimmune patients after anti-B cell therapy.
10 s in vascular research, drug development and cell therapy.
11 a modest benefit in patients receiving stem cell therapy.
12 CRS and other adverse events following CAR T-cell therapy.
13 nciple for therapeutic cloning combined with cell therapy.
14 ial translational significance in adoptive T-cell therapy.
15 for 7.5 months after the initiation of CAR T-cell therapy.
16 erentiation of grafted cells during neonatal cell therapy.
17 studies were safety and tolerability of this cell therapy.
18 showed significant functional improvement by cell therapy.
19 s as an alternative to hepatocytes for liver cell therapy.
20 s contribute to the limited efficacy of stem cell therapy.
21 create cells that are ideal for personalized cell therapy.
22 refractory MLL-B-ALL who receive CD19 CAR-T-cell therapy.
23 derived neural cells in disease modeling and cell therapy.
24 on who would likely benefit from adoptive NK-cell therapy.
25 cytes (CMs) are a promising tool for cardiac cell therapy.
26 etes also impairs reparative responses after cell therapy.
27 onjugate vaccines, bispecific antibodies and cell therapy.
28 anslatable genetic modification strategy for cell therapy.
29 umulation in tumors in a model of adoptive T cell therapy.
30 nts with ischemic heart disease treated with cell therapy.
31 an important step in clinical development of cell therapy.
32 uses on their potential role as new tool for cell therapy.
33 a practical approach to improving SHED-based cell therapy.
34 cently, to investigations of stem/progenitor cell therapy.
35 ransduced, making them viable candidates for cell therapy.
36 ential step to obtain effective products for cell therapy.
37 n of more effective protocols for adoptive T-cell therapy.
38 te safer application of effective CD19 CAR T-cell therapy.
39 oactive infusions a median of 5 days after T cell therapy.
40 al approach for restoring hair cells is stem cell therapy.
41 t of PIRI including CLI with or without stem cell therapy.
42 through genetics and the development of stem-cell therapy.
43 e after chimeric antigen receptor-modified T cell therapy.
44 vival and rejection in preclinical models of cell therapy.
45 l cancer after tumor-infiltrating adoptive T cell therapy.
46 nsion, rest pain, and walking capacity after cell therapy.
47 ticular in organ transplantation and in stem cell therapy.
48 it expected therapeutic benefits of adoptive cell therapy.
49 enome engineering to enhance next-generation cell therapies.
50 for the development of future clinical stem cell therapies.
51 is easily scalable in contrast to adoptive T-cell therapies.
52 lines, which would compromise their use for cell therapies.
53 J-64041757), and chimeric antigen receptor T-cell therapies.
54 elium holds promise for potential autologous cell therapies.
55 uromodulation and experimental gene and stem cell therapies.
56 ent advances opens the way for improved MPhi cell therapies.
57 trials and inform the design of future CAR T cell therapies.
58 strategy for improving the potency of CAR T cell therapies.
59 pporting the feasibility of autologous liver cell therapies.
60 ing of optic neuropathies and development of cell therapies.
61 can potentially be used in autologous liver cell therapies.
62 ckpoint inhibitors, vaccines, and adoptive T-cell therapies.
63 f soluble mediators in the context of immune cell therapies.
64 ll receptor targets in innovative adoptive T cell therapies.
65 development of stem-cell-based engineered T cell therapies.
66 ation design of receptors used in adoptive T cell therapies.
68 Despite the promising efficacy of adoptive cell therapies (ACT) in melanoma, complete response rate
74 lations of engineered T cells for adoptive T-cell therapies and enable in vivo tracking and retrieval
75 fforts to improve the efficacy of adoptive T-cell therapies and immune checkpoint therapies in myelog
77 e approaches to enhance the efficacy of stem cell therapies and to overcome issues with cell therapy
78 New avenues of exploration include cardiac cell therapy and cellular reprogramming targeting cell d
81 It has also pioneered the concepts of stem cell therapy and immunotherapy as a tool against cancer.
82 nterfere with immune cells used for adoptive cell therapy and may limit expected therapeutic benefits
83 s that potentially limit mutation-specific T-cell therapy and may require high-avidity TCRs that are
85 T cells enhances the efficacy of adoptive T cell therapy and suggests a new therapeutic strategy for
86 pecific intracellular antigens without using cell therapy and suggests that epitope spreading could c
87 al trials, clarifying the perception of stem cell therapy and the risks of bone marrow harvest, and d
89 itive ion channels in the heart (via gene or cell therapy) and illumination of the cardiac surfaces (
90 erapeutic success in the field of hMSC-based cell therapy, and an optimal approach for hMSC-based cel
91 TCR/CD3, as a cornerstone compound in anti-T-cell therapy, and anti-TNF-alpha, as the most prominent
93 logic feature can be exploited in allogeneic cell therapy, and the recognition of "missing-self" on t
100 r, the underlying mechanisms of iPSC-derived cell therapy are still unclear, and limited engraftment
101 ing results for HSCT and mesenchymal stromal cell therapy as alternatives to systemic therapies and a
102 illustrate the potential use of SLAMF7-CAR T-cell therapy as an effective treatment against multiple
103 the potential clinical benefit of adoptive T-cell therapy (ATCT) of CMV phosphoprotein 65 (pp65)-spec
106 of the AML patients receiving adoptive NK-92 cell therapy block anti-leukemia cytotoxicity of NK-92 c
108 The disease is a potential target for stem cell therapy but success is likely to be limited by the
109 ciated self-antigens that are amenable for T-cell therapy, but also allows TCR targeting of the cance
111 nt cells may contribute to the efficacy of T-cell therapy by maintaining effector function and promot
116 nic stimulation in tumors and after adoptive cell therapy, CD8 TCR signaling and Nur77GFP induction i
117 Application of miR-146b combined with stem cell therapy could enhance regeneration of cartilaginous
118 Umbilical cord-mesenchymal stem/stromal cell therapy decreased nicotinamide adenine dinucleotide
120 nts with fistulizing CD, mesenchymal stromal cell therapy deposits MSCs locally, into fistulizing tra
121 trategies to increase PCs and exogenous stem cell therapies designed to improve regenerative capacity
123 therapeutic agents as well as vaccine and T-cell therapies directed at mesothelin are undergoing cli
124 were randomly assigned to receive autologous cell therapy (endothelial cells, n = 4) or control treat
126 cted organ damage and deaths following CAR T-cell therapy first highlighted the possible dangers of t
127 nical ventilation a median of 6 days after T cell therapy; five met criteria for acute respiratory di
129 ance the efficacy of vaccines and adoptive T cell therapies for cancer and infectious diseases or, co
130 nalyses have recently arisen in the field of cell therapies for cardiovascular repair and regeneratio
131 espite encouraging preliminary results, stem cell therapies for patients with CHD should only be cons
134 success of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies represents a paradi
136 Conclusions and Relevance: Although stem cell therapy for cardiovascular disease is not yet ready
138 evaluating safety and efficacy of autologous cell therapy for intractable peripheral arterial disease
142 t challenge for the continued development of cell therapy for Parkinson's disease (PD) is the establi
144 rome occurred in 46% of patients following T cell therapy for relapsed/refractory acute lymphoblastic
145 ss with chimeric antigen receptor-modified T cell therapy for relapsed/refractory acute lymphoblastic
147 potential as an autologous, multifunctional cell therapy for stroke, which is the primary cause of l
149 bronchoalveolar lavage were reduced in both cell therapy groups, despite a reduction in bronchoalveo
150 s the gold standard treatment modality, stem cell therapy has been gaining ground as a complimentary
151 c antigen receptor (CAR)-modified adoptive T-cell therapy has been successfully applied to the treatm
152 regenerative medicine mediated by adult stem cell therapy has gathered momentum fueled by tantalizing
160 y no longer be guaranteed because autologous cell therapy has the potential to modify the natural his
165 ansplantation (HSCT) and mesenchymal stromal cell therapy have been proposed for patients with refrac
167 marrow transplantation and mesenchymal stem cell therapy, have entered into early clinical trials.
168 splanting autologous beta-cells for diabetes cell therapy, highlighting the unique advantages and cha
170 ne marrow by flow cytometry after CD19 CAR-T-cell therapy; however, within 1 month of CAR-T-cell infu
173 ed catheter-directed delivery of endothelial cell therapy in a porcine model of cirrhosis for liver r
174 itioned medium (CM-MSC) as an alternative to cell therapy in an antigen-induced model of arthritis (A
179 rolled preclinical trials of unmodified stem cell therapy in large animal models of myocardial ischem
180 melanoma antigens before and after adoptive cell therapy in melanoma patients, we observe a greater
182 riers to the clinical implementation of stem cell therapy in patients with cardiovascular disease and
183 rs facing the routine implementation of stem cell therapy in patients with cardiovascular disease is
184 chimeric antigen receptor-modified T (CAR-T) cell therapy in patients with chronic lymphocytic leukem
185 d transendocardial injection of ixmyelocel-T cell therapy in patients with heart failure and reduced
186 ently being examined in clinical trials as T cell therapy in patients with inflammatory bowel disease
189 vices may improve the effectiveness of CAR T cell therapy in solid tumors and help protect against th
190 e considered during the design of adoptive T cell therapies, including use of engineered T cells.
192 replacement, autologous and allogeneic stem cell therapy, innovations in cancer biology, revertant m
193 well as the unaddressed integration of CAR T-cell therapy into conventional anticancer treatments.
196 ABSTRACT: Autologous cardiac progenitor cell therapy is a promising alternative approach to curr
197 CD4(+)CD25(+)Foxp3(+) regulatory T (Treg) cell therapy is a promising approach for the treatment o
203 Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is highly promising but requires robust T-c
204 y, the general application of current CAR-T--cell therapy is limited by serious treatment-related tox
205 in solid tumors, the full potential of CAR T cell therapy is limited by the availability of cell surf
206 Despite important achievements to date, stem cell therapy is not yet ready for routine clinical imple
207 small-scale studies have suggested that stem-cell therapy is safe and effective in patients with live
208 nd beta-cells is crucial for developing stem cell therapies, islet regeneration strategies, and thera
209 when generating T-cell lines for adoptive T-cell therapy, it avoids the loss of those clones, which
210 r drug targeting, gene delivery, cancer stem cell therapy, magnetic drug targeting and ultrasound-med
211 se strategies could help overcome unresolved cell therapy manufacturing challenges and complement fra
214 able strategy to improve anti-tumor adoptive cell therapy may be to engineer tumor-restricted T cells
215 al studies; it suggests that the benefits of cell therapy may be underestimated or even overlooked if
216 tion of fetal neural precursors suggest that cell therapy may offer a cure for this devastating neuro
218 of low survivability in current cardiac stem cell therapies, mechanical and metabolic, were explored.
219 of regenerating appropriate connections for cell therapy.Midbrain dopaminergic neurons (mDAs) in the
222 that FRbeta is a promising target for CAR T-cell therapy of AML, which may be augmented by combinati
224 g cells (ECFCs) are promising candidates for cell therapy of ischemic diseases, as less than 10% of p
230 ndividual patient data reported no effect of cell therapy on left ventricular function or clinical ou
233 cise changes to gene expression for gene and cell therapies or fundamental studies of gene function.
235 The Pulmonary Hypertension and Angiogenic Cell Therapy (PHACeT) trial was a phase 1, dose-escalati
236 Mechanisms of regulatory B cells and their cell therapy potential are important to decipher in expe
237 cells are a bone marrow-derived, allogeneic, cell therapy product that modulates the immune system, a
238 sed as a reference for characterizing future cell therapy products destined to treat endothelial dysf
242 ll randomized controlled trials) showed that cell therapy reduced the risk of amputation by 37%, impr
244 int blockade and chimeric antigen receptor T cell therapies represent a turning point in cancer immun
250 y enrolled in the CCTRN TIME (Cardiovascular Cell Therapy Research Network Timing in Myocardial Infar
251 t protein inhibition, vaccines, and adoptive cell therapy seem to activate more specific T cells that
253 anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractor
255 SCs) are ideal cell sources for personalized cell therapies since they can be expanded to generate la
256 fusion and nuclear reprogramming may aid in cell therapy strategies for skeletal muscle diseases.
259 eir families and discussing participation in cell therapy studies are described, including participat
261 o the modest functional benefits observed in cell-therapy studies by regulating the amount of contrac
262 of our knowledge, ixCELL-DCM is the largest cell therapy study done in patients with heart failure s
263 her alone or used in, combination with other cell therapies (such as hematopoietic stem cells or bone
265 al framework for the development of targeted cell therapies that can be customized to any clinical ap
266 ssociated with low levels of autoimmunity to cell therapies that can induce damaging cross-reactivity
268 wever, it remains largely unknown how anti-B cell therapy thwarts autoimmunity in these pathologies.
269 anslational therapeutic strategies including cell therapy, tissue engineering, and regenerative medic
270 e safety and efficacy of mesenchymal stromal cell therapies to allow the translation of this research
272 sequently, TECs are an attractive target for cell therapies to restore effective immune system functi
273 ategies to improve and tailor Treg cells for cell therapy to induce transplantation tolerance are hig
274 lecules may expand the scope of engineered T-cell therapy to solid tumors, as well as indications bey
277 cardial Infarction Evaluation) was the first cell therapy trial sufficiently powered to determine if
278 s for recruitment of patients with stroke in cell therapy trials is complex and requires extensive di
279 This study summarizes the use of adoptive cell therapy, tumor vaccines, immune checkpoint inhibito
280 hematologic complete remission (CR) after T-cell therapy, upon emergence of (p190)BCR-ABL-specific T
282 safety and efficacy of an adoptive CD4(+) T-cell therapy using an MHC class II-restricted, HLA-DPB1*
284 rapy, and an optimal approach for hMSC-based cell therapy using non-viral vectors has not been establ
291 on in low-contamination applications such as cell therapies, where good manufacturing practice compat
292 fficacy of chimeric antigen receptor (CAR) T cell therapies, which redirect T cells to solid tumors.
293 oint toward a future when antigen-specific T-cell therapies will play a central role in alloHSCT.
296 imaging-guided catheter-directed endothelial cell therapy with an intraportal technique for the treat
297 ory large B-cell lymphoma who received CAR T-cell therapy with axi-cel had high levels of durable res
298 function in animal models of heart failure; cell therapy, with autologous bone marrow derived mononu
299 that a combination of alpha-4-1BB and CAR T-cell therapy would result in improved antitumor response
300 ration, and differentiation of cells in stem cell therapies, wound healing, and the treatment of canc
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。